Sitaxsentan sodium , 98% , 210421-74-2

Synonym(s):
N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]-3-thiophenesulfonamide sodium salt;Sitaxsentan sodium salt;TBC-11251 sodium salt;Thelin

CAS NO.：210421-74-2

Empirical Formula: C18H14ClN2NaO6S2

Molecular Weight: 476.89

MDL number: MFCD11040990

PRODUCT Properties

• storage temp.: room temp
• solubility: H2O: soluble10mg/mL (clear solution)
• form: powder
• color: white to beige

Description and Uses

In November Encysive Pharmaceuticals launched Thelin® (sitaxsentan sodium) in the U.K. for the treatment of pulmonary arterial hypertension (PAH), following European Commission approval in August 2006. Sitaxsentan is the first selective endothelin A (ETA) receptor antagonist, and the first once-daily oral treatment available for patients with PAH. It is 6,500-fold selective in the targeting of ETA versus ETB receptors. Sitaxsentan is indicated for improving exercise capacity in PAH patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. In the U.S., Encysive has submitted a complete response to an approvable letter received from the FDA in July.

Selective endothelin A (ETA) receptor antagonist. Antihypertensive. Used in treatment of chronic heart failure.

Safety

• WGK Germany: 3
• RTECS: XN0296600